. 2023 May 17;23(3):1–146.

Table 21:

Severe Maternal Adverse Outcomes: TRIAGE PlGF Test

Study	Outcome	Group	Revealed	Concealed	Difference
Triage PlGF test
PARROT^{37, 58}	Severe maternal adverse outcomes (defined by the fullPIERS consensus), % (n/N)	Total	3.8 (22/573)	5.4 (24/446)	1.0^a; aOR (95% CI), 0·32 (0·11–0·96); P = ·043
		PlGF < 12^c	6.2 (8/130)	5.7 (6/106)	aOR 0.87 (0.09–8.02)
		PlGF 12–100^c	3.8 (8/212)	6.9 (12/173)	aOR: 0.15 (0.03–0.92)
		PlGF > 100^c	2.6 (6/229)	3.8 (6/156)	aOR: 0.29 (0.02–4.34)
PARROT Ireland³⁶	Maternal morbidity composite % (n/N)	Total	32.5 (330/1017)	38.02 (457/1202)	Risk ratio (95% CI), 1.01 (0.76– 1.36)
MAPPLE^38,b	Adverse maternal outcomes, % (n/N)	Total	11.9 (47/396)	10.1 (29/287)	Risk ratio (95% CI), 1.17 (0.76–1.82)
		PlGF < 12^c	21.6 (25/116)	17.4 (12/69)	4.2^a
		PlGF 12-100^c	11.7 (16/137)	8.2 (8/97)	3.5^a
		PlGF > 100^c	4.2 (6/143)	7.4 (9/121)	3.2^a

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; fullPIERS, Preeclampsia Integrated Estimate of Risk; PlGF, placental growth factor.

Absolute percent difference as calculated by Frampton et al¹⁴

Unadjusted indirect comparison.

pg/mL

Source: Adapted from Frampton et al.¹⁴